HF
ATRA icon

HRT Financial’s Atara Biotherapeutics ATRA Stock Holding History

HRT Financial’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,691
Closed -$60K – 2298
2023
Q4 		$60K Buy
+4,691
New +$109K ﹤0.01% 1937
2023
Q3 		– Sell
-6,477
Closed -$260K – 2381
2023
Q2 		$260K Buy
+6,477
New +$366K ﹤0.01% 1712
2023
Q1 		– Sell
-1,790
Closed -$146K – 2474
2022
Q4 		$146K Sell
1,790
-3,623
-67% -$378K ﹤0.01% 2003
2022
Q3 		$511K Buy
+5,413
New +$608K 0.01% 1424
2021
Q3 		– Sell
-693
Closed -$269K – 3259
2021
Q2 		$269K Buy
+693
New +$247K ﹤0.01% 2214
2020
Q1 		– Sell
-1,961
Closed -$807K – 767
2019
Q4 		$807K Buy
+1,961
New +$676K 0.03% 400

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HRT Financial's ATRA Position: Q1 2024 in Review

HRT Financial sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 4,691 shares — an estimated $60K sold.

HRT Financial first reported a position in ATRA in Q4 2019 and held it in 6 quarters. The position peaked at $807K in Q4 2019. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • HRT Financial reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • HRT Financial sold 4,691 Atara Biotherapeutics shares in Q1 2024, an estimated $60K.
  • HRT Financial first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 6 quarters.
  • HRT Financial's Atara Biotherapeutics position peaked at $807K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on HRT Financial's 13F filing for Q1 2024, filed 13 May 2024.